Al Hammadi Co. for Development and Investment’s net income fell 39 percent year-on-year to SAR 63.95 million in the first nine months of 2016.
The decline is attributed to the increase in depreciation expenses and financial charges after the opening of the new hospital in August and the closure of Al Hammadi Hospital in Olaya in the first and second quarter of this year.
Item | 9m 2015 | 9m 2016 | Change |
---|---|---|---|
Revenues | 403.64 | 423.59 | 4.9 % |
Gross Income | 172.17 | 168.78 | (2.0 %) |
Operating Income | 103.17 | 80.23 | (22.2 %) |
Net Income | 105.58 | 62.47 | (40.8 %) |
Average Shares | 160.00 | 160.00 | - |
EPS (Riyals) | 0.66 | 0.39 | (40.8 %) |
Third quarter profit was down 22.5 percent to SAR 21.5 million year-on-year. Compared to the previous quarter, profit gained 2.6 percent.
Item | Q3 2015 | Q3 2016 | Change |
---|---|---|---|
Revenues | 136.80 | 141.35 | 3.3 % |
Gross Income | 57.97 | 56.48 | (2.6 %) |
Operating Income | 31.92 | 25.97 | (18.6 %) |
Net Income | 27.69 | 20.73 | (25.1 %) |
Average Shares | 160.00 | 160.00 | - |
EPS (Riyals) | 0.17 | 0.13 | (25.1 %) |
Period | Revenues | Change | Gross Income | Change | Net Income | Change | EPS(Riyal) |
---|---|---|---|---|---|---|---|
Q1 2016 | 144.16 | 11.3 % | 54.75 | 8.1 % | 21.14 | (48.5 %) | 0.13 |
Q2 2016 | 138.08 | 0.5 % | 57.56 | (9.5 %) | 20.63 | (44.1 %) | 0.13 |
Q3 2016 | 141.35 | 3.3 % | 56.48 | (2.6 %) | 20.73 | (25.1 %) | 0.13 |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
Q1 2016 | 42.42 % | 30.79 % | 21.09 % |
Q2 2016 | 41.32 % | 30.64 % | 18.24 % |
Q3 2016 | 40.74 % | 29.96 % | 16.90 % |
Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
---|---|---|---|---|
Q1 2016 | 160.00 | 0.76 | 0.76 | 8.80 |
Q2 2016 | 160.00 | 0.66 | 0.66 | 8.37 |
Q3 2016 | 160.00 | 0.61 | 0.61 | 8.50 |
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
Q1 2016 | 36.41 | 36.41 | 3.14 |
Q2 2016 | 45.86 | 45.86 | 3.60 |
Q3 2016 | 36.32 | 36.32 | 2.62 |
2016
Period | healthy services and other | Pharmaceutical sales revenue - Pharmacies |
---|
Item | Q3 2016 (e) | Q3 2016 (a) | Change |
---|---|---|---|
Average | 24.08 | 20.73 | (13.9 %) |
Item | Q3 2016 (e) | Q3 2016 (a) | Change |
---|---|---|---|
AlJazira Capital | 22.10 | 20.73 | (6.2) % |
Albilad Capital | 23.00 | 20.73 | (9.9) % |
SFC | 24.00 | 20.73 | (13.6) % |
Alistithmar Capital | 24.40 | 20.73 | (15.0) % |
Al Rajhi Capital | 25.00 | 20.73 | (17.1) % |
Sico | 26.00 | 20.73 | (20.3) % |
Current | |
Market Cap (M Riyal) | 7,512.00 |
Enterprise Value (EV) (M) | 7,510.11 |
Shares Outstanding ((M)) | 160.00 |
EPS ( Riyal) (TTM) | 1.79 |
Book Value (BV) ( Riyal) | 11.58 |
Par Value ( Riyal) | 10.00 |
Adjusted P/E (Last12) | 26.88 |
P/E (TTM) | 26.27 |
Price/book | 4.05 |
Return on Average Assets (%) (TTM) | 11.1 |
Return on Average Equity (%) (TTM) | 15.9 |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}